Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, announces that Professor Lindy Durrant, Joint CEO of Scancell, is scheduled to present on SCIB1, the Company’s clinical stage ImmunoBody® vaccine for the treatment of melanoma, and the ImmunoBody® technology platform at the following conferences:
| Conference |
Presentation |
Timing |
| 3rd Annual Cancer Vaccines Conference, London, UK (15-16 September 2014) |
Phase I/II trial of a novel antibody DNA immunotherapy, SCIB1 ImmunoBody® which targets CD64, in the treatment of melanoma |
15 September 2014 at 15.20 |
| Cancer Antibodies Vaccines/Adjuvants & Delivery Conference (CAVAD 14), Lausanne, Switzerland (17-19 September 2014) |
Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of melanoma |
17 September 2014 at 11.30 |
| 14th International Conference on Progress in Vaccination Against Cancer (PIVAC-14), Rome, Italy (24-26 September 2014) |
Phase 1/2 clinical trial of SCIB1 ImmunoBody® in stage III/IV melanoma |
TBC |
Professor Lindy Durrant will also be on the Scientific Advisory Panel and conference co-chair at CAVAD 14.
For Further Information:
| Dr Richard Goodfellow, Joint CEO |
Scancell Holdings Plc |
+44 (0) 74 2323 0 497 |
| Professor Lindy Durrant, Joint CEO |
Scancell Holdings Plc |
|
| Mo Noonan/Simon Conway |
FTI Consulting |
+44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.